LB Pharmaceuticals Appoints Minako Pazdera, J.D., Ph.D. as General Counsel

NEW YORK, Jan. 21, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals, Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a clinical-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depression, and other neuropsychiatric diseases, today announced the appointment Dr. Minako Pazdera as General Counsel.

Dr. Pazdera joins LB Pharmaceuticals with more than 25 years of experience spanning corporate governance, intellectual property, strategic corporate transactions and compliance.

“We are delighted to welcome Minako to LB Pharmaceuticals,” said Heather Turner, Chief Executive Officer. “Dr. Pazdera has broad expertise encompassing both financial and strategic transactions, as well a deep understanding of intellectual property law and corporate compliance. Her contributions will be invaluable as we advance the development of LB-102 and work towards our broader vision of building a fully integrated CNS-focused company.”

Before joining LB Pharmaceuticals, Dr. Pazdera served as General Counsel and Corporate Secretary at Kardigan. Previously, she was General Counsel and Corporate Secretary at Carmot Therapeutics where she led the legal function during its dual track IPO/strategic transaction process, resulting in the acquisition of Carmot by Roche for up to $3.1 billion in 2024. Her earlier roles encompassed both strategic and intellectual property functions at Lyell Immunopharma, Sangamo Therapeutics and Genentech, as well as in private practice. Dr. Pazdera holds a J.D. from the Fordham University School of Law, a Ph.D. in Biological Sciences from Carnegie Mellon University, and a B.A. in Molecular and Cell Biology from the University of California, Berkeley.

Dr. Pazdera added: “I am excited to join LB Pharmaceuticals during this pivotal period in the Company’s trajectory. LB is poised to initiate key clinical programs that will advance its goal to provide new treatment options for patients with complex neuropsychiatric disorders. I look forward to collaborating with the rest of the team to develop innovative medicines in areas of high unmet need.”

About LB-102

LB-102 is a Phase 3-ready oral, small molecule and a methylated derivative of amisulpride. In early 2025, LB Pharmaceuticals announced positive data from a four-week placebo-controlled, double-blinded, Phase 2 trial in patients with acute schizophrenia. The Phase 2 trial demonstrated statistically significant benefit versus placebo at all doses studied, a potentially class leading safety profile among D2 antagonists and partial agonists, and positive effects on negative symptoms and cognition. LB-102 is advancing into a Phase 3 clinical trial for acute schizophrenia and a Phase 2 clinical trial for bipolar depression. Additional expansion opportunities for LB-102 could include major depressive disorder (MDD), predominantly negative symptoms of schizophrenia, Alzheimer’s disease psychosis and agitation, as well as bipolar mania and cognitive impairment associated with schizophrenia.